Document is current
Any future updates will be listed below
-
Authors
Hluchý, Milan
Gajdušková, Pavla
Ruiz de los Mozos, Igor https://orcid.org/0000-0003-4097-6422
Rájecký, Michal https://orcid.org/0000-0002-0865-4012
Kluge, Michael
Berger, Benedict-Tilman https://orcid.org/0000-0002-3314-2617
Slabá, Zuzana
Potěšil, David
Weiß, Elena https://orcid.org/0000-0001-9252-5629
Ule, Jernej
Zdráhal, Zbyněk
Knapp, Stefan https://orcid.org/0000-0001-5995-6494
Paruch, Kamil
Friedel, Caroline C. https://orcid.org/0000-0003-3569-4877
Blazek, Dalibor https://orcid.org/0000-0003-4662-9982
- License Information
-
More Information
Article History
Received: 22 October 2021
Accepted: 8 August 2022
First Online: 14 September 2022
Competing interests
: B.-T.B. is a co-founder and the CEO of CELLinib. D.B. has received a consulting fee from Proxygen. The other authors declare no competing interests.
